ArticleFrontiers in pharmacology2026

GPER1 as a therapeutic target in MASLD: evidence for steatosis attenuation by agonist G1 in preclinical models.

Yifang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.